公开(公告)号：US20200318120A1

公开(公告)日：2020-10-08

申请号：US16615552

申请日：2018-05-23

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Mats ANDER ,  Magnus BERGMAN ,  Tomas BJORKMAN ,  Joakim GALLI ,  Gustav RODRIGO

IPC: C12N15/62 ,  C07K1/22 ,  C07K14/31

Abstract: A recombinant protein comprising a functional polypeptide and, linked to the N-terminus of said functional polypeptide, an N-terminal spacer having a length such that the number of amino acid residues between a signal peptide cleaving site and an N-terminus proximal structural unit of said functional polypeptide is 14-24.

公开(公告)号：US20200299326A1

公开(公告)日：2020-09-24

申请号：US16893574

申请日：2020-06-05

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav José Rodrigo ,  Tomas Bjorkman ,  Mats Ander ,  Jesper Ulf Hansson

IPC: C07K1/22 ,  C07K16/00 ,  C07K14/31 ,  B01J20/28 ,  B01J20/24 ,  B01D15/38 ,  C07K17/10 ,  B01J20/286 ,  B01J20/32 ,  C07K16/06

Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.

公开(公告)号：US10751645B2

公开(公告)日：2020-08-25

申请号：US15882998

申请日：2018-01-29

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Carina Engstrand ,  Annika Forss ,  Gunnar Glad ,  Bo-Lennart Johansson ,  Hans J Johansson ,  Jean-Luc Maloisel

IPC: B01D15/38 ,  B01D15/32 ,  B01D15/36 ,  B01J20/32 ,  B01J20/286 ,  B01J41/20 ,  C07K1/36 ,  C07K16/06 ,  C07K1/16 ,  C07K16/00

Abstract: The present invention relates to a chromatography ligand defined by the following formula R1—R2—N(R3)—R4—R5 wherein R1 is a substituted or non-substituted phenyl group; R2 is a hydrocarbon chain comprising 0-4 carbon atoms; R3 is a hydrocarbon chain comprising 1-3 carbon atoms; R4 is a hydrocarbon chain comprising 1-5 carbon atoms; and R5 is OH or H. The invention also comprises a separation matrix, comprising the described ligands coupled to a porous support, such as particles or a membrane. The ligand and matrix according to the invention is useful for purification of biomolecules or organic compounds, such as proteins, polypeptides, DNA etc. An advantageous use according to the invention is the purification of antibodies.

公开(公告)号：US10711035B2

公开(公告)日：2020-07-14

申请号：US16682855

申请日：2019-11-13

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav José Rodrigo ,  Tomas Bjorkman ,  Mats Ander ,  Jesper Ulf Hansson

IPC: A23J1/00 ,  C07K1/22 ,  C07K16/00 ,  C07K14/31 ,  B01J20/28 ,  B01J20/24 ,  B01J20/32 ,  B01D15/38 ,  C07K17/10 ,  B01J20/286 ,  C07K16/06

Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.

公开(公告)号：US10654887B2

公开(公告)日：2020-05-19

申请号：US15282367

申请日：2016-09-30

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Gustav Jose Rodrigo ,  Tomas Bjorkman ,  Mats Ander ,  Jesper Ulf Hansson

IPC: C07K1/22 ,  B01J20/26 ,  C07K16/00 ,  C07K14/31 ,  B01J20/32 ,  B01J20/285 ,  B01J20/286 ,  C07K16/12 ,  C07K17/10

Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.

公开(公告)号：US20200079878A1

公开(公告)日：2020-03-12

申请号：US16594731

申请日：2019-10-07

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav Rodrigo ,  Tomas Bjorkman ,  Mats Ander

IPC: C07K16/46 ,  C07K16/00 ,  C07K14/31 ,  C07K1/22 ,  C07K16/06 ,  B01D15/38 ,  B01J20/32 ,  B01J20/289

Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52 wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO:4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.

公开(公告)号：US10513537B2

公开(公告)日：2019-12-24

申请号：US16096952

申请日：2017-05-10

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav José Rodrigo ,  Tomas Bjorkman ,  Mats Ander ,  Jesper Ulf Hansson

IPC: A23J1/00 ,  C07K1/22 ,  C07K16/00 ,  C07K14/31 ,  B01J20/28 ,  B01J20/24 ,  B01D15/38 ,  C07K16/06 ,  C07K17/10

Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.

公开(公告)号：US20190381480A1

公开(公告)日：2019-12-19

申请号：US16486653

申请日：2018-02-15

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Ronnie Palmgren ,  Jean-Luc Maloisel ,  Gustav Rodrigo ,  Tomas Bjorkman

IPC: B01J20/286 ,  B01D15/38 ,  B01J20/28 ,  B01J20/32 ,  B01D15/18 ,  C07K1/22

Abstract: A separation matrix comprising porous particles to which antibody-binding protein ligands have been covalently immobilized, wherein the density of said ligands is above 5 mg/ml, the volume-weighted median diameter of said porous particles is at least 10 and below 30 μm and the said porous particles have a gel phase distribution coefficient, expressed as KD for dextran of molecular weight 110 kDa, of 0.5-0.9.

公开(公告)号：US20190144496A1

公开(公告)日：2019-05-16

申请号：US16096869

申请日：2017-05-10

Applicant: GE HEALTHCARE BIOPROCESS R&D AB

Inventor： Gustav José Rodrigo ,  Tomas Bjorkman ,  Mats Ander

IPC: C07K1/22 ,  C07K17/10 ,  B01J20/285 ,  B01J20/286 ,  C07K16/12 ,  B01J20/26 ,  C07K14/31 ,  C07K16/00

Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52, wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO: 4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.

公开(公告)号：US20190060869A1

公开(公告)日：2019-02-28

申请号：US16189894

申请日：2018-11-13

Applicant: GE Healthcare BioProcess R&D AB

Inventor： Martin Hall ,  Sture Larsson ,  Andreas Muranyi ,  Gustav Rodrigo ,  Jinyu Zou ,  Per-Mikael Aberg

IPC: B01J20/24 ,  B01D15/38 ,  C07K16/00 ,  B01J20/32 ,  C07K17/10 ,  B01J20/28 ,  B01J20/285 ,  B01J20/289 ,  C07K14/31 ,  C07K1/22 ,  B01J20/286 ,  C07K17/00

CPC classification number: B01J20/24 ,  B01D15/3809 ,  B01J20/28019 ,  B01J20/285 ,  B01J20/286 ,  B01J20/289 ,  B01J20/3212 ,  B01J20/3219 ,  B01J20/3274 ,  B01J20/3293 ,  B01J2220/52 ,  B01J2220/54 ,  C07K1/22 ,  C07K14/31 ,  C07K16/00 ,  C07K17/00 ,  C07K17/10 ,  C07K2317/55

Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.